[go: up one dir, main page]

ATE367165T1 - Xanthangummi enthaltende reepithelialisierende pharmazeutische zubereitungen - Google Patents

Xanthangummi enthaltende reepithelialisierende pharmazeutische zubereitungen

Info

Publication number
ATE367165T1
ATE367165T1 AT02425274T AT02425274T ATE367165T1 AT E367165 T1 ATE367165 T1 AT E367165T1 AT 02425274 T AT02425274 T AT 02425274T AT 02425274 T AT02425274 T AT 02425274T AT E367165 T1 ATE367165 T1 AT E367165T1
Authority
AT
Austria
Prior art keywords
gum
xanthang
reepithelializing
pharmaceutical preparations
preparations containing
Prior art date
Application number
AT02425274T
Other languages
English (en)
Inventor
Maria Grazia Mazzone
Grazia Paladino
Clara Marino
Ornella Peri
Vincenzo Enea
Original Assignee
Sifi Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sifi Spa filed Critical Sifi Spa
Application granted granted Critical
Publication of ATE367165T1 publication Critical patent/ATE367165T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/723—Xanthans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02425274T 2002-04-30 2002-04-30 Xanthangummi enthaltende reepithelialisierende pharmazeutische zubereitungen ATE367165T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02425274A EP1358883B8 (de) 2002-04-30 2002-04-30 Xanthangummi enthaltende reepithelialisierende pharmazeutische Zubereitungen

Publications (1)

Publication Number Publication Date
ATE367165T1 true ATE367165T1 (de) 2007-08-15

Family

ID=28799773

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07108593T ATE528009T1 (de) 2002-04-30 2002-04-30 Reepithelialisierende pharmazeutische zusammensetzungen, die xanthangummi enthalten
AT02425274T ATE367165T1 (de) 2002-04-30 2002-04-30 Xanthangummi enthaltende reepithelialisierende pharmazeutische zubereitungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT07108593T ATE528009T1 (de) 2002-04-30 2002-04-30 Reepithelialisierende pharmazeutische zusammensetzungen, die xanthangummi enthalten

Country Status (15)

Country Link
US (5) US8912164B2 (de)
EP (2) EP1358883B8 (de)
JP (2) JP4837912B2 (de)
CN (1) CN100502884C (de)
AT (2) ATE528009T1 (de)
AU (1) AU2003230224B2 (de)
BR (1) BR0304655A (de)
CA (2) CA2749172C (de)
DE (2) DE60221227T2 (de)
DK (1) DK1358883T3 (de)
ES (2) ES2290264T3 (de)
MX (1) MXPA04010668A (de)
PT (1) PT1358883E (de)
RU (1) RU2297230C2 (de)
WO (1) WO2003092706A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60221227T2 (de) * 2002-04-30 2008-01-31 Sifi S.P.A., Lavinaio-Aci Xanthangummi enthaltende reepithelialisierende pharmazeutische Zubereitungen
US20050142208A1 (en) 2002-05-09 2005-06-30 Won Min Yoo Pharmceutical composition for treatment of wounds conntaining blood plasma or serum
WO2006035969A1 (ja) * 2004-09-28 2006-04-06 Senju Pharmaceutical Co., Ltd. キサンタンガムおよびアミノ酸を含有する眼科用組成物
ITRM20050443A1 (it) * 2005-08-12 2007-02-13 Opocrin Spa Preparati oftalmici a base di polisaccaridi mucoadesivi con capacita' riepitelizzante della cornea.
US7323184B2 (en) 2005-08-22 2008-01-29 Healagenics, Inc. Compositions and methods for the treatment of wounds and the reduction of scar formation
KR101381035B1 (ko) 2006-03-23 2014-04-04 센주 세이야꾸 가부시키가이샤 잔탄검 및 글루코스를 포함하는 안약 조성물
EP2309980A1 (de) * 2008-07-08 2011-04-20 S.I.F.I. Societa' Industria Farmaceutica Italiana Ophthalmische zusammensetzungen zur behandlung von erkrankungen des hinteren augensegments
JP5620168B2 (ja) * 2010-06-30 2014-11-05 Ｄｓｐ五協フード＆ケミカル株式会社 キシログルカン−カチオン複合体及びそれを含有する安定化組成物
IT1404145B1 (it) * 2010-12-27 2013-11-15 Altergon Sa Composizioni di acido ialuronico stabilizzate verso l'azione di degradazione del calore o degli enzimi
US20140315836A1 (en) * 2011-11-24 2014-10-23 Toyo Sugar Refining Co., Ltd. Protective agent for keratoconjunctiva or suppressive agent for keratoconjunctival disorder
CN107529760B (zh) * 2015-05-18 2021-05-07 柿原秀己 抗菌物质、液状抗菌剂以及液状抗菌剂的制造方法
CN108472351A (zh) * 2015-12-29 2018-08-31 英特维特国际股份有限公司 球虫病疫苗
CN106236704A (zh) * 2016-08-30 2016-12-21 上海昊海生物科技股份有限公司 一种兼具仿生和靶向功能的莫西沙星滴眼液及其制备方法
EP3982930A1 (de) 2019-06-11 2022-04-20 SIFI S.p.A. Mikroemulsionszusammensetzungen
IT202000002296A1 (it) * 2020-02-06 2021-08-06 Sifi Spa Formulazioni topiche oftalmiche a base di xantano con ridotta posologia
IT202000015457A1 (it) * 2020-06-26 2021-12-26 Sifi Spa Composizione oftalmica e suo uso nel trattamento di patologie dell’occhio
MX2021003369A (es) * 2021-03-22 2022-09-23 Laboratorios Grin S A De C V Lágrima ocular triple.
IT202200000821A1 (it) * 2022-01-19 2023-07-19 Sifi Spa Formulazioni topiche oftalmiche a base di xantano con ridotta posologia

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136177A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
US4370324A (en) 1980-09-17 1983-01-25 Bernstein Joel E Method and composition for treating and preventing irritation of the eyes
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4711780A (en) * 1984-06-11 1987-12-08 Fahim Mostafa S Composition and process for promoting epithelial regeneration
US4826872A (en) 1986-12-03 1989-05-02 Takeda Chemical Industries, Ltd. Pharmaceutical composition for treatment of cataract
JPH0723317B2 (ja) * 1988-03-17 1995-03-15 生化学工業株式会社 角膜上皮層障害症治療剤
JPH0651638B2 (ja) * 1989-02-13 1994-07-06 新技術事業団 角膜上皮創傷治療用点眼剤
US5271943A (en) * 1989-10-27 1993-12-21 Scott Health Care Wound gel compositions containing sodium chloride and method of using them
IT1243435B (it) * 1990-10-05 1994-06-10 Altergon Sa Composizioni farmaceutiche per uso topico comprendenti acido ialuronico sale sodico e sostanze disinfettanti
US5804213A (en) * 1991-10-09 1998-09-08 Lectec Corporation Biologically active aqueous gel wound dressing
US6277365B1 (en) * 1997-09-18 2001-08-21 Bausch & Lomb Incorporated Ophthalmic composition including a cationic glycoside and an anionic therapeutic agent
AU2797400A (en) * 1999-01-19 2000-08-07 Dr. Gerhard Mann Chemisch-Pharmazeutische Fabrik Gmbh Artificial lacrimal fluid in gel form
WO2002015913A1 (en) * 2000-08-23 2002-02-28 Phairson Medical, Inc. Treatment of trauma, and other indications
WO2002049611A2 (en) * 2000-12-20 2002-06-27 Alcon, Inc. Ophthalmic lubricating solution adapted for use in lasik surgery
DE60221227T2 (de) * 2002-04-30 2008-01-31 Sifi S.P.A., Lavinaio-Aci Xanthangummi enthaltende reepithelialisierende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
CA2484020C (en) 2011-10-25
CN100502884C (zh) 2009-06-24
JP4837912B2 (ja) 2011-12-14
US8912164B2 (en) 2014-12-16
US20080139502A1 (en) 2008-06-12
JP2005529906A (ja) 2005-10-06
DE60221227D1 (de) 2007-08-30
EP1913948B1 (de) 2011-10-12
US20080139522A1 (en) 2008-06-12
DE07108593T1 (de) 2008-12-04
AU2003230224A1 (en) 2003-11-17
CA2749172A1 (en) 2003-11-13
RU2297230C2 (ru) 2007-04-20
DE60221227T2 (de) 2008-01-31
WO2003092706A1 (en) 2003-11-13
ES2290264T3 (es) 2008-02-16
PT1358883E (pt) 2007-10-01
US20080146530A1 (en) 2008-06-19
US20050234011A1 (en) 2005-10-20
CA2484020A1 (en) 2003-11-13
ATE528009T1 (de) 2011-10-15
BR0304655A (pt) 2004-07-20
MXPA04010668A (es) 2005-06-20
JP2011102315A (ja) 2011-05-26
EP1358883B8 (de) 2007-10-03
CN1649602A (zh) 2005-08-03
EP1913948A1 (de) 2008-04-23
EP1358883B1 (de) 2007-07-18
ES2304913T3 (es) 2012-03-01
US20160166601A1 (en) 2016-06-16
ES2304913T1 (es) 2008-11-01
RU2004131550A (ru) 2005-06-10
EP1358883A1 (de) 2003-11-05
DK1358883T3 (da) 2007-11-12
AU2003230224B2 (en) 2008-07-17
JP5203472B2 (ja) 2013-06-05
CA2749172C (en) 2013-04-09

Similar Documents

Publication Publication Date Title
ATE367165T1 (de) Xanthangummi enthaltende reepithelialisierende pharmazeutische zubereitungen
HRP20060240T3 (en) Intranasal formulation of rotigotine
ATE464880T1 (de) Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
IS6344A (is) Lyfjasamsetningar sem leiða til aukinna lyfjastyrkja
ATE471144T1 (de) Intranasale verabreichung von schnell wirkendem insulin
CY1108532T1 (el) Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
RS52169B (en) STABLE LAKVINIMOD PREPARATIONS
BR0210519A (pt) Composições farmacêuticas de adsorvatos de fármaco amorfo
MXPA03006841A (es) 4-fluoro-n-indan-2-il-benzamida y su uso como producto farmaceutico.
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
ATE179884T1 (de) Viskoelastische zusammensetzungen aus organischen fluorierten verbindungen
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
ATE447397T1 (de) Darreichungsform mit erhöhter bioverfügbarkeit
IL208697A0 (en) Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
BR0304298A (pt) Composição contendo um ácido orgânico cosmeticamente ativo e um produto de legume
DE50010978D1 (de) Kosmetische Stiftzubereitung
AR057648A1 (es) Composicion de metaflumizona para la administracion topica
AR031649A1 (es) Composicion farmaceutica de dronedarona para administracion parenteral
EP1269978A3 (de) Verwendung von Bis-Resorcinyltriazinderivaten in kosmetischen oder dermatologischen Zubereitungen
ATE412404T1 (de) Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
BRPI0412453A (pt) uso do ácido ascórbico ou um sal fisiologicamente aceitável do mesmo
SE0203817D0 (sv) New composition
DE60112578D1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase